Takeda to invest more than 100 million Euros in dengue vaccine manufacturing plant

01-Dec-2016 - Takeda Pharmaceutical Company Limited announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany. This represents a major step by Takeda toward meeting important unmet needs in dengue prevention. According to ...

UCL and Takeda announce a new research partnership

Aims the identification of novel therapeutic targets for neurodegenerative diseases

15-Oct-2015 - UCL (University College London) and Takeda Pharmaceutical Company Limited announced a new research collaboration to identify and validate novel target genes for the treatment of neurodegenerative disease. This collaboration will focus on mechanistic approaches for the identification of genes or ...

Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification

24-Jan-2011 - Evotec AG announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR ...

Approval of Additional Indication of NESINA: Combination Therapy with Thiazolidinediones for Type 2 Diabetes in Japan

24-Aug-2010 - Takeda Pharmaceutical Company Limited announced that an additional indication for “NESINA®” (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare. NESINA, a dipeptidyl peptidase-IV (DPP-4) ...

Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin for Treatment of Type 2 Diabetes

31-Aug-2009 - Takeda Pharmaceutical Company Limited and Takeda Global Research & Development Center, Inc., a wholly owned United States subsidiary, jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular ...

Takeda Reacquires Rights to Diabetes Drug in Canada

25-Aug-2009 - Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999. "Reacquiring ...

Kinaxo Biotechnologies Enters Agreement with Takeda

23-Apr-2008 - Kinaxo Biotechnologies announced that it has entered an agreement with Takeda San Diego, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement, Kinaxo will make its KinaTor(TM) technology available to Takeda researchers involved in drug ...